Business, energy, technology, markets and global industry news from Business News Today

VGA039

PharmaDeviceNews VGA039
Incyte’s acquisition of Vega Therapeutics adds the Phase 3 monoclonal antibody VGA039 to its hematology pipeline, strengthening its strategy in von Willebrand disease treatment. Representative image.
Pharma & Biotech

Incyte closes $2bn Vega Therapeutics deal as VGA039 reshapes VWD strategy

Incyte has acquired Vega Therapeutics and Phase 3 VWD antibody VGA039. Explore the clinical promise, deal strategy and risks ahead.

Read More
Representative image: Laboratory research into blood-clotting disorders highlights Star Therapeutics’ VGA039 programme as complete Phase 1/2 von Willebrand disease data head to ISTH 2026.
Pharma & Biotech

Why Star Therapeutics’ complete VGA039 dataset matters for the future of von Willebrand disease care

See why Star Therapeutics’ complete VGA039 data at ISTH 2026 could reshape von Willebrand disease prophylaxis and Incyte’s strategy.

Read More
Pharma & Biotech

Why Star Therapeutics’ FDA win for VGA039 could reshape the von Willebrand disease treatment race.

Star Therapeutics won dual FDA designations for VGA039 in von Willebrand disease. Read what it could change, and what still needs proving.

Read More